Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03757000
Recruitment Status : Recruiting
First Posted : November 28, 2018
Last Update Posted : December 10, 2018
Sponsor:
Information provided by (Responsible Party):
Shanghai YingLi Pharmaceutical Co. Ltd.

Brief Summary:
Protocol YY-20394-001 is a phase I open-label, first in human, dose escalation study to assess the tolerability, pharmacokinetics (PK) and efficacy of YY-20394 in patients with relapse or refractory B cell malignant hematological tumor.

Condition or disease Intervention/treatment Phase
B-cell Lymphoma Recurrent B-cell Chronic Lymphocytic Leukemia Drug: YY-20394 Phase 1

Detailed Description:

This is a two-part study comprised of a dose escalation part and a dose expansion part.

In the dose escalation part single patient cohorts will be dosed until a single related toxicity of Grade ≥ 3 or a Dose Limiting Toxicity (DLT) is observed. If this occurs, the study will switch to a conventional oncology 3+3 design (3 patients per dose cohort, with the potential to add an additional 3 patients if toxicity is observed) and escalation will continue until the maximum tolerated dose (MTD) is reached and a recommended Phase II (RP2D) dose is determined. Once the MTD is established a separate dose expansion part will enroll up total additional 12 patients at the RP2D.

In this clinical trial, YY-20394 is given orally once daily. A treatment cycle is defined as 28 days. YY-20394 was given until disease progression, unacceptable toxicity, or withdrawal from the study. The protocol was initiated with a single-patient cohort, treated with oral YY-20394 20 mg once daily (QD). Subsequent cohorts used a 3+3 design and evaluated doses of 40-320mg QD. Adverse events (AEs) were graded by NCI-CTCAE v4.0. Efficacy was assessed according to IWG-NHL and CLL consensus response criteria.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Intervention Model: Single Group Assignment
Intervention Model Description: dose escalation
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of YY-20394 Given Orally to Patients With Relapsed or Refractory B Cell Hematologic Malignancies
Actual Study Start Date : December 25, 2017
Estimated Primary Completion Date : March 30, 2019
Estimated Study Completion Date : May 30, 2019


Arm Intervention/treatment
Experimental: YY-20394

YY-20394 is a selective inhibitor of the delta isoform of phosphatidylinositol 3- kinase (PI3Kδ).

YY-20394 for clinical use is presented as a sterile tablets at 20 mg, or 100 mg doses. The drug product is intended for oral administration.Preset cohorts of 3-6 subjects will be enrolled sequentially at doses of 20, 40, 80, 140, 200, 260 and 320 mg/day.

Drug: YY-20394
YY-20394 is a new type of PI3K-δ selective inhibitor which differs structurally from idelalisib and its analogs, showing high potency against PI3Kδ, but with markedly improved selectivity (>1,000-fold selectivity for PI3K-δ versus PI3Kγ). This higher selectivity for PI3Kδ may decrease the risk of serious infection seen with idelalisib and especially with duvelisib due to strong immune suppression.Preclinical evaluation has demonstrated improved efficacy and safety for YY-20394 compared to idelalisib.




Primary Outcome Measures :
  1. Dose limited toxicities evaluated with NCI-CTC AE v4.0 [ Time Frame: within 28 days after the first dose ]
    Incidence of dose limited toxicities and associated dose of YY-20394

  2. Adverse events evaluated by NCI CTCAE v4.0 [ Time Frame: from the first dose to within 30 days after the last dose ]
    Incidence of adverse events and associated dose of YY-20394


Secondary Outcome Measures :
  1. Plasma concentration of YY-20394 [ Time Frame: within 56 days after the first dose ]
    This composite endpoint will measure the plasma concentration of YY-20394.

  2. Objective response rate [ Time Frame: within 30 days after the last dose ]
    the proportion of subjects who have a Complete Response or Partial Response

  3. Disease control rate [ Time Frame: within 30 days after the last dose ]
    the proportion of subjects who have a Complete Response or Partial Response



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Males and/or females over age 18
  2. Histologically or cytologically confirmed B cell malignancies
  3. Eastern Cooperative Oncology Group performance status of 0 to 2
  4. Life expectancy of at least 3 months
  5. At least one measurable lesion by Computed Tomography(CT) or Magnetic Resonance Imaging(MRI) according to, which is not in irradiated area (only for expansion phase)
  6. Acceptable hematologic status:

    Absolute neutrophil count(ANC)≥1.0×109/L; Platelet count(PLT)≥70×109/L; Hemoglobin(Hb)≥80 g/L; Total bilirubin(TBIL)≤1.5×Upper limit of normal value(ULN); Alanine aminotransferase(ALT)≤1.5×ULN; Aspartate aminotransferase(AST)≤1.5×ULN; Blood urea nitrogen(BUN)≤1×ULN; Creatinine(Cr)≤1×ULN; Left Ventricular Ejection Fractions(LVEF)≥50%; QTcF:male<450 ms,female<470 ms

  7. The washout period from the last time accepting any anti-tumor treatment (including radiation therapy, chemotherapy, hormone therapy, surgery, or molecular targeted therapy) to participating in this test should be 4 weeks or more.
  8. The last time participate in an investigational drug or device study should be more than one month prior to study entry.
  9. Ability to understand the purposes and risks of the study
  10. Availability of the signed informed consent forms (ICFs) approved by the investigator's Institutional Review Board (IRB)/Independent Ethics Committee (IEC) of the study site obtained before entering the study.

Exclusion Criteria:

  1. Previously treated with PI3Kδ inhibitors and cause disease progression.
  2. Any anti-tumor treatment, within 4 weeks prior to study entry.
  3. There are third interstitial effusions (such as massive pleural effusion and ascites) which can not be controlled by drainage or other methods.
  4. The dosage of steroid hormone (prednisone equivalent) was greater than 20mg/ days, and lasted for more than 14 days.
  5. Medical history of difficulty in swallowing, malabsorption, or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
  6. During the study period, drugs that may prolong the QT (such as anti arrhythmic drugs) could not be interrupted.
  7. Patients with central nervous system (CNS) involvement.
  8. Allergy, or known to be allergic to the drug.
  9. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy(such as pneumonia).
  10. Known infection with human immunodeficiency virus (HIV), hepatitis B virus(HBV), or hepatitis C virus (HCV).
  11. History of immunodeficiency, including HIV positive test, other acquired or congenital immunodeficiency disorders, organ transplantation or allogeneic bone marrow transplantation.
  12. Autologous hematopoietic stem cell transplantation was received within 90 days before the first dose treatment.
  13. Has suffered from any heart disease, including: (1) angina pectoris; (2) medicated or clinically significant arrhythmia; (3) myocardial infarction; (4) heart failure; (5) any other heart disease judged by the researchers not suitable for the test.
  14. The baseline pregnancy test was positive in pregnant women, lactating women or fertile women.
  15. According to the judgement of the researcher, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of the study (such as severe hypertension, diabetes, thyroid diseases, etc.).
  16. Receiving granulocyte colony-stimulating factor(GCSF) or blood transfusion within 7 days before screening.
  17. Patients suffering from other primary malignant tumors in the past 5 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03757000


Contacts
Layout table for location contacts
Contact: Hanying Bao, MD,PhD 86 21-51370693 hybao@yl-pharma.com
Contact: Yuanyuan Xu, M.S. 86 21-51320088 ext 8588 yyxu@yl-pharma.com

Locations
Layout table for location information
China, Beijing
Peking Cancer Hospital Recruiting
Beijing, Beijing, China, 100142
Contact: Yuqin Song, MD,PhD    86 10-88140650    songyuqin622@163.com   
Contact: Meifeng Tu, MD,PhD    86 10-88121122    44329472@qq.com   
Principal Investigator: Yuqin Song, MD,PhD         
Sub-Investigator: Meifeng Tu, MD,PhD         
Sub-Investigator: Lingyan Ping, MD,PhD         
China, Jiangsu
Jiangsu Province Hospital Not yet recruiting
Nanjing, Jiangsu, China, 210029
Contact: Jiangyong Li, MD,PhD    86 25-83714511    lijianyonglm@126.com   
Contact: Wei Xu, MD,PhD    86 25-83714511    xuwei0484@jsph.org.cn   
Principal Investigator: Jianyong Li, MD,PhD         
Sub-Investigator: Meifeng Tu, MD,PhD         
China, Tianjin
Hematology Hospital of Chinese Academy of Medical Sciences Recruiting
Tianjin, Tianjin, China, 300020
Contact: Lugui Qiu, MD,PhD    86 22-23909172    qiulg@ihcams.ac.cn   
Contact: Junyuan Qi, MD,PhD    86 22-23909999    qijy@ihcams.ac.cn   
Principal Investigator: Lugui Qiu, MD,PhD         
Sub-Investigator: Junyuan Qi, MD,PhD         
Sponsors and Collaborators
Shanghai YingLi Pharmaceutical Co. Ltd.
Investigators
Layout table for investigator information
Study Director: Hanying Bao, PhD Shanghai YingLi Pharmaceutical Co. Ltd.

Additional Information:
Publications of Results:

Layout table for additonal information
Responsible Party: Shanghai YingLi Pharmaceutical Co. Ltd.
ClinicalTrials.gov Identifier: NCT03757000     History of Changes
Other Study ID Numbers: YY-20394-001
First Posted: November 28, 2018    Key Record Dates
Last Update Posted: December 10, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Shanghai YingLi Pharmaceutical Co. Ltd.:
YY-20394
B-cell Lymphoma Recurrent

Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, B-Cell
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Lymphoma, Non-Hodgkin
Lymphoma